anticoagulation

Ajabnoor, A. M., Parisi, R., Zghebi, S. S., Ashcroft, D. M., Faivre-Finn, C., Morris, C., et al. (2023). Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019. Cancer. http://doi.org/10.1002/cncr.35152

View

Apenteng, P. N., Prieto-Merino, D., Hee, S. W., Lobban, T. C., Caleyachetty, R., & Fitzmaurice, D. A. (2023). Optimising prediction of mortality, stroke, and major bleeding for patients with atrial fibrillation: validation of the GARFIELD-AF tool in UK primary care electronic records. Br J Gen Pract, 73, e816-e824. http://doi.org/10.3399/bjgp.2023.0082

View

Mendonca, S. C., Edwards, D. A., Lund, J., Saunders, C. L., & Mant, J. (2023). Progression of stroke risk in patients aged <65 years diagnosed with atrial fibrillation: a cohort study in general practice. Br J Gen Pract. http://doi.org/10.3399/bjgp.2022.0568

View

Hunt, N. B., Pajouheshnia, R., Salih, A., van Doorn, S., Souverein, P. C., Bazelier, M. T., et al. (2023). Prescribing of Low-dose Rivaroxaban in Patients with Atherosclerotic Cardiovascular Disease in the United Kingdom and the Netherlands. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15708

View

van den Dries, C. J., Pajouheshnia, R., van den Ham, H. A., Souverein, P., Moons, K. G. M., Hoes, A. W., et al. (2022). Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15534

View